How MSI and TMB Factor into Current Biomarker Testing PanelsVideo Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Dr Andrey Antov provides a useful metaphor to explain how genetic testing and genomic testing differ from one another and the purpose behind each type of testing.
Linda Bosserman provides insight into positive data around payer-provider collaborations